The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations

Sci Rep. 2024 Oct 26;14(1):25452. doi: 10.1038/s41598-024-76591-8.

Abstract

In cancer research, RAS biology has been focused on only a handful of tumor types. While RAS genes have long been suspected as common contributors to a wide spectrum of cancer types, robust evidence is required to firmly establish their critical oncogenic significance. We present a data mining study using DepMap genome-wide CRISPR screening data, which provide substantial evidence to support the prominent pervasive oncogenic role and tissue-specific permissiveness of RAS gene mutations. Differential analysis of CRISPR effect scores identifies K- or N-RAS genes as the most differential gene in contrasts of (K-, N-, combined) RAS mutant versus wild-type cell lines across multiple tissue types. The distinguished tissue-specific pattern of KRAS vs. NRAS as top differential genes in subsets of tissue types and evidence from genome data supported the idea of KRAS- and NRAS-engaged tissue types. To our knowledge, this is the first report of prominent pervasive oncogenic role of RAS mutations revealed by gene dependency data that is beyond the current understanding of the oncogenic role of RAS genes and their well-known involved tissue types. Our findings strongly support RAS mutations as primary oncogenic drivers beyond traditionally recognized cancer types and offer insights into their tissue-specific permissiveness.

MeSH terms

  • Carcinogenesis / genetics
  • Cell Line, Tumor
  • GTP Phosphohydrolases / genetics
  • GTP Phosphohydrolases / metabolism
  • Genes, ras
  • Humans
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mutation*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Oncogenes
  • Organ Specificity / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • NRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • Membrane Proteins
  • KRAS protein, human
  • GTP Phosphohydrolases